Результаты поиска

Brain stem and cerebellar atrophy in chronic progressive neuro-Behçet's disease.

PURPOSE: Chronic progressive neuro-Behçet's disease (CPNBD) resembles multiple sclerosis (MS) on patient background and image findings, and therefore is difficult to diagnose. The purpose is to identify the characteristic magnetic resonance imaging (MRI) findings of CPNBD and to clarify the differences between the MRI findings of CPNBD and those of MS. MATERIALS AND METHODS: The subjects consist of a CPNBD group (n=4; 1 male and 3 females; mean age, 51 y.o.), a MS group (n=19; 3 males and 16 females; mean age, 45 y.o.) and a normal control group (n=23; 10 males and 13 females; mean age, 45 y.…

Biomarkers of progressive multiple sclerosis decrease following autologous hematopoietic stem cell transplantation.

BACKGROUND: Autologous hematopoietic stem cell transplantation (AHSCT) has been increasingly used for treatment of relapsing-remitting multiple sclerosis (RRMS). Existing data suggest that AHSCT might alter the natural course of multiple sclerosis (MS) and postpone or even prevent the occurrence of progressive MS. This study aimed to investigate whether three cerebrospinal fluid biomarkers of progressive MS: Galectin-9, GDF-15, and YKL-40, were affected by treatment intervention with AHSCT for RRMS. METHODS: RRMS patients treated with AHSCT at Uppsala University Hospital between 2011 and 2018…

N, N'-Dicyclohexyl-N-linoleic Acylurea, an Unsaturated Fatty Acid Derivative Alleviates Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice.

Multiple sclerosis is a chronic inflammatory disease characterized by demyelination in the central nervous system (CNS). The existing drugs for multiple sclerosis treatment carry significant side effects. The aim of this study was to investigate the safety and effect of a new compound N, N'-dicyclohexyl-N-linoleic acylurea (DCLAA) on experimental autoimmune encephalomyelitis (EAE), the principal multiple sclerosis animal model. Results showed that DCLAA had low toxicity, and DCLAA significantly inhibited the EAE progression and reduced the dosage requirements of methylprednisolone. After DCLAA…

Сосредоточься на нормальной белой и серой материи в многоклерозовом мозге: связь с мрачным развитием.

Множественный склероз представляет собой хроническое нейро-воспалительное и нейродегенеративное заболевание, традиционно характеризующееся наличием в ЦНС точечных демиелинизирующих повреждений. Однако накопление доказательств указывает на то, что многократная склерозовая патофизиология выходит за рамки таких классических повреждений, поражая также «нормальную» видимую ткань как в белой, так и в серой материи, называемую соответственно «обычной белой материей» и «обычной серой материей». Здесь мы представляем всеобъемлющий обзор широко распространенных биохимических, клеточных и микроструктурны

Совпадение в аннотации оригинала
Multiple sclerosis is a chronic neuro-inflammatory and neurodegenerative disease, traditionally characterized by the presence of focal demyelinating lesions in the CNS. However, accumulating evidence suggests that multiple sclerosis pathophysiology extends beyond such classical lesions, affecting also 'normal' appearing tissue in both white and gray matter, …

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.

BACKGROUND: Delaying time to requiring a wheelchair in people living with MS is an important treatment goal to maintain quality of life and guard against increased healthcare costs. In this post hoc analysis, the effects of siponimod versus placebo on time to sustained Expanded Disability Status Scale (EDSS) ≥ 7.0 over the core part of the Phase 3 EXPAND study were assessed. METHODS: The time to sustained EDSS ≥ 7.0 (time to requiring a wheelchair) was analysed for participants with secondary progressive multiple sclerosis (SPMS). Analyses were based on a While on Treatment (WOT) set that cen…

Added value of spinal cord MRI in detecting active disease in non-relapsing progressive multiple sclerosis patients.

INTRODUCTION: Spinal cord MRI is not routinely recommended in the monitoring of MS. In patients with progressive MS (pMS), presence of disease activity is an important predictor of treatment response to currently approved treatments. The aim of this study was to investigate the added usefulness of spinal cord MRI in the identification of active disease in patients with non-relapsing pMS. METHODS: MRI records were reviewed in a cohort of pMS patients. All patients with at least 2 years of follow-up with the same MRI scanner were included in the study. Patients with clinical relapses during fol

Фрейлти испытает инвалидность при прогрессивном множественном склерозе.

ОКРУЖАЮЩАЯ СРЕДА: Оценка хрупкости при сильном прогрессивном множественном склерозе (ПМС) и изучение основополагающих механизмов. МЕТОДЫ: Это перспективное, сквозное, многоцентральное исследование охватывало позднюю серьёзную группу ПМС, нуждающуюся в квалифицированном уходе (n = 53), и группу ПМС, сравнивающую возраст, пол и продолжительность болезни (n = 53). Участники получили неврологические и МРТ-анализы и представили образцы крови. Площадь была измерена по шкале Эдмонтона. Инвалидность измерялась по расширенной шкале статуса инвалидов (EDSS), а усталость оценивалась по шкале усталости. И

Совпадение в аннотации оригинала
BACKGROUND: To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. METHODS: This prospective, cross-sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration-matched control PMS group (n = 53). Participants received neurolog…

Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study.

Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression in a real-world cohort of SPMS patients treated with natalizumab (NTZ) or interferon beta-1b (IFNb-1b). This multicenter retrospective enrolled patients with a diagnosis of SPMS according to 2014 Lublin criteria, who received NTZ or IFNb-1b for at least 48 months between the 1st June 2012 and the 15th May 2018 ​at 33 Italian MS centers contributing to the Italian MS Registry NT

Сравнительная эффективность Ublitixumab Versus Natalizumab в лечении повторного слапса и излучающего множественный склероз.

Релапсирующий множественный склероз (RRMS) — хроническое аутоиммунное расстройство, характеризующееся иммунной обезвоживанием и нейродегенерацией, приводящее к прогрессивному неврологическому расстройству. Регулярная терапия (ДМТ) играет ключевую роль в управлении ОСР путем снижения частотности рецидивов и замедления развития инвалидности. Среди них моноколональные антитела, такие, как ublituximab и atalizumab, стали ключевыми терапевтическими вариантами с различными механизмами действий и профилями безопасности. Целью этого описательного обзора является сопоставление эффективности, безопаснос

Совпадение в аннотации оригинала
Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune disorder characterized by immune-mediated demyelination and neurodegeneration, leading to progressive neurological impairment. Disease-modifying therapies (DMTs) play a crucial role in managing RRMS by reducing relapse frequency and slowing disability progression. Among these, monoclonal a…

Refractory epilepsy following natalizumab associated PML.

Natalizumab treatment of multiple sclerosis (MS) is associated with a risk of developing progressive multifocal leukoencephalopathy (PML), a rare opportunistic viral demyelinating disease caused by reactivation of John Cunningham virus (JCV). Herein, we report a case of a 40-year-old woman who developed refractory temporal lobe epilepsy; one year after recovery form Natalizumab-induced PML. Localisation related epilepsy, which may be refractory in nature, as in this case report, is a potential chronic disabling complication of PML. Epilepsy in this context, likely reflects grey matter involvem…

Systemic Sclerosis with Multiple Pulmonary Manifestations.

Systemic sclerosis (SSc) is a chronic autoimmune multisystem disorder characterized by endothelial dysfunction and fibroblast dysfunction, which results in progressive fibrosis of the skin and internal organs more frequently the lungs and gastro intestinal tract. Pulmonary involvement is common in the course of SSc, with Interstitial Lung Disease (ILD) and Pulmonary Arterial Hypertension (PAH) being the leading causes of death. Here we report, case of an elderly female patient presenting with Diffuse SSc with multiple uncommon pulmonary manifestations like ILD with Usual Interstitial Pneumonia

Optic neuropathy in sarcoidosis.

Five patients with isolated optic neuropathy and sarcoidosis are discussed. The spectrum of clinical disease was variable but two groups could be identified: patients with chronic progressive visual loss which was associated with thickening of the optic nerve and was refractory to steroid treatment, and patients with acute or subacute optic neuropathy in which the visual loss responded rapidly to steroids. In the latter group steroid dependence developed in all three of the patients. In none did the clinical picture resemble that of the optic neuritis associated with multiple sclerosis.

Effects of 16-week progressive resistance training on neurodegeneration in people with progressive multiple sclerosis: An extended baseline within-person trial.

BACKGROUND: Progressive multiple sclerosis (PMS) is characterized by ongoing neurodegeneration, which current therapies inadequately address. Exercise therapy has emerged as a potential approach to mitigate this process. OBJECTIVES: To investigate the effects of a 16-week progressive resistance training (PRT) on neurodegeneration and neuronal function in people with PMS. METHODS: In this extended-baseline within-person trial, neurodegeneration and neuronal function were assessed (i.e. total brain volume (TBV), cortical and deep gray matter volume (CGMV & DGMV) normalized for intercranial vol…

Calcium-phosphate homeostasis in secondary progressive multiple sclerosis patients during mitoxantrone therapy.

OBJECTIVES: To assess calcium-phosphate parameters in SPMS patients treated with mitoxantrone (MTX). METHODS: Thirty eight SPMS patients eligible for MTX therapy in the Department of Neurology in Zabrze, Poland were enrolled in a prospective study from March 2016 to November 2019. The parameters of serum calcium-phosphate metabolism and the neurological status according to the Expanded Disability Status Scale (EDSS) were assessed. In patients with hypovitaminosis D, vitamin D (VitD) supplementation was introduced (4000 IU/day for 1 month and later 2000 IU /day). RESULTS: Most patients were w

Measuring Treatment Response in Progressive Multiple Sclerosis-Considerations for Adapting to an Era of Multiple Treatment Options.

Disability in multiple sclerosis accrues predominantly in the progressive forms of the disease. While disease-modifying treatment of relapsing MS has drastically evolved over the last quarter-century, the development of efficient drugs for preventing or at least delaying disability in progressive MS has proven more challenging. In that way, many drugs (especially disease-modifying treatments) have been researched in the aspect of delaying disability progression in patients with a progressive course of the disease. While there are some disease-modifying treatments approved for progressive multi…

Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: A note of caution.

Knowledge about complications of chronic ultra-high dose vitamin D supplementation is limited. We report a patient with primary progressive multiple sclerosis (MS) who presented with generalized weakness caused by hypercalcemia after uncontrolled intake of more than 50,000 IU of cholecalciferol per day over several months. Various treatment strategies were required to achieve normocalcemia. However, renal function improved only partly and further progression of MS was observed. We conclude that patients need to be informed about the risks of uncontrolled vitamin D intake and neurologists need …

Demyelinating disease after neurologically complicated primary Epstein-Barr virus infection.

This report describes five patients who, following a neurologically complicated primary Epstein-Barr virus infection, developed progressive or relapsing neurologic deficits. The sequelae in four patients followed 4 to 12 years led to the diagnosis of multiple sclerosis (MS). The fifth patient presented with acute disseminated sclerosis and exhibits diffuse neurologic deficits that have persisted for 2 years. We suggest that the diagnosis of an unexplained acute neurologic or psychiatric syndrome should raise the question of a primary EBV etiology. A precisely timed serologic and hematologic st…

Новая потенциальная ось лиганда-рецептора, связанная с ремонтом тканей в качестве терапевтических целей в прогрессивном множественном склерозе.

Прогрессивный множественный склероз (MS) представляет собой ухудшающуюся фазу заболевания, характеризующуюся увеличением нейродегенерации и инвалидностью и главным образом отказом от текущего лечения. Поиск вариантов лечения по-прежнему сопряжен с определенными трудностями не только из-за отсутствия понимания патогенных механизмов, но и из-за того, что ранние догмы были сосредоточены на нейроинфламмации, что затмевало важнейшую роль процесса ремонта тканей. Цель по ремонту тканей должна начинаться на раннем этапе развития болезней, а терапевтические стратегии для прогрессивных MS должны сочета

Совпадение в аннотации оригинала
Progressive multiple sclerosis (MS) represents the worsening phase of the disease, characterized by increasing neurodegeneration and disability and mainly refractory to current treatments. Finding therapeutic options remains challenging partially not only because of the lack of understanding of pathogenic mechanisms but also because the early dogma was cente…

Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis.

BACKGROUND: Rapid tapping tests have been shown to be reliable measures of upper motor neuron disease, and effectively examine motor function differences between multiple sclerosis (MS) and non-MS controls (CON), and between relapsing-remitting and progressive MS subtypes. To successfully perform rapid repetitive movements such as tapping, a person must be able to consistently turn on and off motor units to switch between the up and down movement phases. However, it is not clear which specific movement phase that occurs during tapping is different between MS subtypes. The objective of this stu…

Prothrombin and factor X are elevated in multiple sclerosis patients.

Animal models have implicated an integral role for coagulation factors in neuroinflammatory diseases such as multiple sclerosis (MS) beyond their role in hemostasis. However, their relevance in humans requires further elucidation. This study aimed to determine whether levels of coagulation factors differ between patients with neuroimmunological disorders and respective controls. Individuals suffering from relapsing-remitting and secondary progressive MS had significantly higher prothrombin and factor X levels than healthy donors, whereas levels were unchanged in primary progressive MS and neur…